Beijing Fresenius Kabi Pharmaceutical Co., Ltd.

Our product range is broad, including intravenous drugs, infusion therapy, clinical nutrition, and the medical devices needed to apply these products. In the field of biosimilars, we focus on autoimmune diseases and oncology. In 2019, Fresenius Kabi’s first biosimilar was successfully launched. In terms of blood transfusion medicine and cell therapy equipment, Fresenius Kabi provides blood component collection and in vitro cell therapy products. We take care of life as our mission and are committed to providing medical staff with essential medicines and technologies, and helping them find high-quality solutions to difficult problems